New hope for breast cancer survivors: drug targets debilitating hot flashes

NCT ID NCT06917313

Recruiting now Symptom relief Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This study tests a daily pill called fezolinetant to see if it can reduce hot flashes in breast cancer survivors who are on hormone therapy. About 92 women with early-stage breast cancer will be randomly assigned to receive either the drug or a placebo. The main goal is to measure how much the frequency of hot flashes decreases after 12 weeks of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITING

Columbus, Ohio, 43201, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Yale University
RECRUITING

New Haven, Connecticut, 06511, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3)